Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia
TMEM16 단백질을 억제하는 약물은 SARS-CoV-2 스파이크 유도 융합체를 차단합니다
Article
[키워드] Activation
alveolar
approved drug
calcium
Cell
Cell fusion
cell surface
Characteristics
COVID-19
COVID-19 disease
defined
Deterioration
diarrhoea
disease
drug
effective
effective drug
effective drugs
include
Inflammatory response
inhibit
inhibited
inhibitor
inhibitors
ion channel
lung
Lung function
Lungs
membrane
membrane conductance
morphology
niclosamide
oedema
Pathogenesis
patients with COVID-19
performed
pharmacological
Phosphatidylserine
plasma membrane
pneumocyte
potential mechanism
Protein
repurposing
responsible
SARS-CoV-2
SARS-CoV-2 spike protein
Screening
screenings
Spike protein
Support
Syncytia
the cell
the SARS-CoV-2
therapy
thrombosis
unique
virus replication
[DOI] 10.1038/s41586-021-03491-6 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41586-021-03491-6 PMC 바로가기 [Article Type] Article